Johnson & Johnson (JNJ) Weekday Company Research Note

Company: Johnson & Johnson

Symbol: JNJ

Sector: Healthcare

Industry: Drug Manufacturers – General

Source: Financial Modeling Prep, as of 2026-07-13T21:10:20+00:00.

Business Overview

Johnson & Johnson is a healthcare holding company engaged in the research, development, manufacture, and sale of healthcare products. According to the supplied company description from Financial Modeling Prep, the company operates through the Innovative Medicine and MedTech segments. Innovative Medicine focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. MedTech includes products used in interventional solutions, orthopaedics, surgery, and vision categories.

Supplied Market and Financial Snapshot

• Recent price: $257.77
• Market capitalization: $620.5B
• Revenue: $94.2B
• Net income: $26.8B
• Operating income: $25.6B
• Free cash flow: $19.7B
• Cash: $19.7B
• Debt: $47.9B
• Equity: $81.5B
• Quality score: 75

Profitability and Cash Flow

The supplied data indicate strong profitability. Johnson & Johnson reported a net margin of 28.46% and an operating margin of 27.17%. Free cash flow was also positive, with a free cash flow margin of 20.91%. These metrics suggest that the company has generated substantial earnings and cash flow relative to its revenue base in the supplied period.

However, the dataset does not include multi-year margin history, segment-level profitability, research and development trends, litigation reserves, acquisition effects, or guidance. As a result, the durability of these margins cannot be fully evaluated from the supplied evidence alone.

Balance Sheet Position

Johnson & Johnson reported $19.709 billion in cash and $47.933 billion in debt. The supplied debt-to-equity ratio is 0.59. This indicates the company uses debt but is not shown, from the supplied data alone, to be highly levered relative to reported equity.

That said, balance-sheet interpretation is limited without debt maturity schedules, interest expense, credit ratings, pension obligations, off-balance-sheet commitments, or management commentary. The company’s debt load should be monitored, especially in relation to future cash generation and any large acquisitions, legal settlements, or capital allocation decisions.

Quality Assessment

The supplied quality score is 75. Based on the available data, the company appears to combine large scale, positive free cash flow, and strong reported margins. These are favorable characteristics for an established healthcare company, but the score should not be treated as a standalone investment conclusion.

Valuation Context

The supplied market capitalization is $620.509 billion, while revenue is $94.193 billion and net income is $26.804 billion. These figures provide useful context for scale, but the supplied dataset does not include valuation ratios, peer comparisons, dividend information, earnings growth forecasts, analyst estimates, or historical valuation ranges. Therefore, a full valuation opinion is Data Unavailable from the supplied evidence.

Key Strengths

• Scale: Johnson & Johnson has a large reported revenue base and market capitalization.
• Profitability: Supplied margins are strong, including a 28.46% net margin and 27.17% operating margin.
• Cash generation: Free cash flow of $19.698 billion and a 20.91% free cash flow margin are positive indicators in the supplied data.
• Diversified healthcare exposure: The company operates across Innovative Medicine and MedTech, according to the supplied description.

Key Risks and Uncertainties

• Healthcare and regulatory risk: Drug and medical technology companies can face regulatory, reimbursement, product safety, and approval risks. Specific current regulatory issues are Data Unavailable in the supplied dataset.
• Litigation risk: Large healthcare companies can face legal and product liability exposure. Specific litigation status, reserves, or settlement risk are Data Unavailable.
• Debt and capital allocation risk: Debt of $47.933 billion exceeds cash of $19.709 billion in the supplied data. Future borrowing, acquisitions, dividends, buybacks, or legal payments could affect financial flexibility.
• Execution risk: The company’s performance depends on research productivity, product launches, competitive positioning, and MedTech execution. Segment-level growth and pipeline data are Data Unavailable.
• Valuation risk: The company may be high quality yet still produce poor investor returns if the purchase price is too high. A complete valuation framework is limited because peer comparisons and forward estimates are Data Unavailable.

Data Limitations

This note uses only the structured facts supplied in the prompt and cites Financial Modeling Prep as the data source. It does not incorporate news, management filings, conference call commentary, analyst estimates, dividend history, forward guidance, clinical pipeline details, patent timelines, litigation disclosures, or peer-relative valuation metrics. Where evidence is absent, this report states Data Unavailable. Investors should not rely on this note as a complete due diligence package.

Research-Safe View

Based solely on the supplied Financial Modeling Prep data, Johnson & Johnson appears to be a large, profitable healthcare company with strong reported margins and positive free cash flow. A constructive view would be more supportable if an investor independently confirms that the valuation is reasonable, cash generation remains durable, debt is manageable, and segment-level fundamentals remain healthy. A cautious or neutral stance may be appropriate if valuation appears demanding, healthcare-specific risks rise, or margins and free cash flow weaken.

Educational Disclosure

This report is provided for educational and informational purposes only and is not financial, investment, tax, legal, or accounting advice. It is not a recommendation to buy, sell, or hold any security. Investment outcomes are uncertain, and equity securities can decline in value, including the risk of loss of principal. Readers should conduct independent research and consult a qualified financial professional before making investment decisions.